7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Metacrine, Inc
(NASDAQ:MTCR) 

MTCR stock logo

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic ste...

Founded: 2014
CEO: Preston S. Klassen  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Metacrine Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -1.68-1.44-1.2-0.96-0.72-0.48-0.240
Metacrine Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -1.68-1.44-1.2-0.96-0.72-0.48-0.240
Metacrine Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.350.711.061.411.762.122.47
Metacrine P/S ratio ttm
202108 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 01.492.984.475.967.458.9410.44Milllion
Metacrine (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.98-0.84-0.7-0.56-0.42-0.28-0.14-0
Metacrine P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.10.190.290.380.480.570.67
No extra charts and metrics for this ticker.